MedTrace Logo

Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)

NCT02756793 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-12-31

No results posted yet for this study

Summary

A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive metastatic cancers. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).

Conditions

Interventions

RADIATION

Stereotactic Ablative Radiotherapy (SABR)

Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.

OTHER

Standard of Care Treatment

May include: * Continue with current systemic agent(s) * Observation * Switch to next-line treatment Palliative radiotherapy is allowed in this arm.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2022-07-31
Completion
2026-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02756793 on ClinicalTrials.gov